Hephaï has filed a patent application to protect the software technology used in its digital education tool, a Class 1 medical device designed to help asthma and COPD patients to control their condition more effectively. The digital tool is installed as an app and the patient records themselves using the inhaler. The app then analyses the movements and sounds in real time, and feeds back any errors via a virtual coach who makes suggestions on improving inhaler technique, and it is precisely that patient movement analysis software that the patent is seeking to protect. The logic behind the need for this educational approach, offering step-by-step instructions on the correct use of an inhaler, lies in the stats. It is estimated that well over a third of COPD patients use their inhalers incorrectly, which affects how they take their medication and by default adversely affects the benefits.
“It is estimated that well over a third of COPD patients use their inhalers incorrectly“
Hephaï founder and pulmonologist at Pitié-Salpêtrière hospital, Dr. Valéry Trosini-Desert, said: “Innovation is what we are all about. After just one year of R&D we’ve been able to file this patent for France, which marks a first for a digital platform of this type in pulmonology. Our recent partnership with Chiesi, an international pharmaceutical company, with whom we are collaborating to fully develop the platform, proves that there is significant interest in our technology among patients and health professionals.”